Sijimedtec Delivers 'Novosis Trauma' Bone Substitute System to Johnson & Johnson for the First Time

Orthopedic implant research and manufacturing company CJ MedTech announced on the 27th that it has officially started supplying its bone substitute product, NOVOSIS TRAUMA, to Johnson & Johnson MedTech.

The delivery, which took place on the 21st, is a case of expanding the use of products previously used in spinal surgery to the fracture treatment field, based on the bio-regenerative medical technology of its parent company CJ Bio. According to the supply contract, Johnson & Johnson MedTech will be exclusively responsible for product distribution within Korea. CJ MedTech signed an exclusive supply agreement with the global medical device company Johnson & Johnson MedTech last month.

NOVOSIS TRAUMA is a medical device that promotes the formation of new bone. It is composed of hydroxyapatite and recombinant human bone morphogenetic protein-2 (rhBMP-2). Hydroxyapatite acts as a carrier that gradually releases rhBMP-2 at the treatment site, enabling effective bone regeneration even at low doses. This design helps reduce side effects such as ectopic bone formation (bone growth in abnormal locations) and swelling, which can occur with high-dose use.

This product is a bone substitute that simultaneously possesses 'osteoconductivity,' providing an appropriate structure for bone growth, and 'osteoinductivity,' inducing bone formation. It is particularly suitable for regenerating bone defects of 5 cm or less caused by acute upper and lower limb fractures.

Through this product delivery, CJ MedTech has expanded its business portfolio from focusing on orthopedic implant fixation devices to bio-regenerative medical-based treatment solutions. The company plans to gradually strengthen its position in the fracture treatment market by expanding supply to major Southeast Asian countries and developing surgical protocols in collaboration with medical professionals.

According to Medgadget, a U.S. medical technology media outlet, the orthopedic trauma medical device market was approximately $32 billion (about 46 trillion KRW) in 2023 and is expected to grow to about $90 billion (about 131 trillion KRW) by 2036. The main growth factors are analyzed to be the increase in the elderly population, rising prevalence of osteoporosis, and increased sports injuries.

Jung Joo-mi, CEO of CJ MedTech, said, "This delivery is the first meaningful milestone marking the full implementation of the supply contract with Johnson & Johnson MedTech." She added, "Starting with the market supply of NOVOSIS TRAUMA, we will gradually expand not only domestically but also into the global fracture treatment market." She further stated, "We will continue to introduce high-performance bone regeneration solutions that both medical professionals and patients can trust, setting new standards in treatment."

This content was produced with the assistance of AI translation services.